David Murray is the Head of Clinical Innovation at the Kinghorn Centre for Clinical Genomics. His research focuses on discovery and development of innovative molecular diagnostics and potential therapeutics. He has over 15 years’ experience in the biotech and medtech industries specialising in product development and assay validation. David previously developed a liquid biopsy for colorectal cancer at Clinical Genomics (Colvera) and performed the technology transfer of the test into a CLIA laboratory at Bridgewater (NJ) where it is now commercially available. He has a strong understanding of the regulatory environment (ISO, FDA, EMA, ICH, TGA and CLSI etc) and has built and managed medical laboratories. He has also designed studies for trials to support FDA submissions for Colvera and analytical validation of Clinical Genomics’ product InSureOne™, which was a key to its successful FDA 510(k) approval. He completed his MSc in Biostatistics at Sydney University and BSc in Biotechnology from Dublin City University.
- 2023European journal of human genetics : EJHG10.1038/s41431-022-01251-2
Community Genetics screening in a pandemic: solutions for pre-test education, informed consent, and specimen collection.